Compare NTST & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | NVCR |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2020 | 2015 |
| Metric | NTST | NVCR |
|---|---|---|
| Price | $20.76 | $12.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $20.62 | ★ $28.08 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | ★ 150.00 | 21.79 |
| EPS | ★ 0.08 | N/A |
| Revenue | $195,006,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $15.47 | $7.72 |
| Revenue Next Year | $14.57 | $6.74 |
| P/E Ratio | $260.50 | ★ N/A |
| Revenue Growth | ★ 19.79 | 8.28 |
| 52 Week Low | $14.00 | $9.82 |
| 52 Week High | $21.30 | $21.55 |
| Indicator | NTST | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 50.83 |
| Support Level | $17.67 | $12.66 |
| Resistance Level | N/A | $14.13 |
| Average True Range (ATR) | 0.43 | 0.97 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 64.05 | 42.70 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.